NCT03873389View on ClinicalTrials.gov

Ocrelizumab Effects on the Metabolome in MS

CompletedOBSERVATIONAL

Enrollment

25

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

June 22, 2023

Study Completion Date

December 5, 2023

Conditions

Multiple Sclerosis

Interventions

DRUG

Ocrelizumab

Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER